TP-05: An investigational therapeutic for the prevention of Lyme disease2
TP-05 is an oral, systemic formulation of lotilaner in development for the prevention of Lyme disease.2
Currently, there is no FDA-approved pharmacologic option for the prevention of Lyme disease.2
Believed to be the only non-vaccine, drug-based, preventive therapeutic in development that targets and kills infected tick vectors before they can transmit the Borrelia bacteria that causes Lyme disease
An oral formulation intended to rapidly provide systemic blood levels of lotilaner, a well-characterized anti-parasitic agent, for on-demand protection
Currently being evaluated in a Phase 2a trial
Learn more about our efforts to prevent Lyme disease.
1. Tarsus reports full-year 2022 financial results and recent business achievements. News release. Tarsus Pharmaceuticals, Inc. March 13, 2023. Accessed August 11, 2023. https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-reports-full-year-2022-financial-results-and-recent 2. Tarsus Pharmaceuticals, Inc. initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme disease. News release. Tarsus Pharmaceuticals, Inc. June 16, 2021. Accessed August 11, 2023. https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-inc-initiates-phase-1-callisto-trial-tp
Please reach out to us using the form below.
"*" indicates required fields